|
|
|
|
|
Study |
study type
|
Pathology | T1 | T0 | Patients | sample sizes | ROB |
Results |
|
|
|
| |
| CheckMate 451 (N ; all population), 2019 NCT02538666 | RCT | Extensive stage SCLC (Es-SCLC) - maintenance (M) | nivolumab | placebo | patients with extensive-stage disease small cell lung cancer (ED-SCLC) as maintenance therapy after completion of platinum-based chemotherapy | 280 / 275 | some concern
| inconclusive | - suggested 33 % decrease in progression or deaths (PFS)
|
| |
| CheckMate 451 (NI ; all population), 2019 NCT02538666 | RCT | Extensive stage SCLC (Es-SCLC) - maintenance (M) | nivolumab plus ipilimumab | placebo | patients with extensive-stage disease small cell lung cancer (ED-SCLC) as maintenance therapy after completion of platinum-based chemotherapy | 279 / 275 | some concern
| inconclusive | - inconclusive 8 % decrease in deaths (OS) (PE)
- suggested 28 % decrease in progression or deaths (PFS)
|
|
|
| |
| CASPIAN (D ; all population), 2019 NCT03043872 | RCT | Extensive stage SCLC (Es-SCLC) - 1st Line (L1) | durvalumab, etoposide plus either cisplatin or carboplatin | etoposide plus either cisplatin or carboplatin | adults with untreated extensive-stage small-cell lung cancer as First-line treatment | 268 / 269 | some concern
| conclusif | - demonstrated 27 % decrease in deaths (OS) (PE)
- suggested 25 % decrease in deaths (OS) (extension)
- suggested 20 % decrease in PFS (extension)
- suggested 22 % decrease in progression or deaths (PFS)
|
| |
| CASPIAN (DT ; all population), 2019 NCT03043872 | RCT | Extensive stage SCLC (Es-SCLC) - 1st Line (L1) | durvalumab plus tremelimumab and etoposide plus either cisplatin or carboplatin | etoposide plus either cisplatin or carboplatin | adults with untreated extensive-stage small-cell lung cancer (SCLC) | 268 / 269 | some concern
| inconclusive | - inconclusive 18 % decrease in deaths (OS) (PE)
|
|
| |
| IMpower-133, 2018 NCT02763579 | RCT | Extensive stage SCLC (Es-SCLC) - 1st Line (L1) | atezolizumab (as induction and maintenance therapy) plus carboplatin and etoposide | placebo plus carboplatin and etoposide | patients with extensive-Stage Small-Cell Lung Cancer who had not received previous systemic treatment | 201 / 202 | low
| conclusif | - demonstrated 30 % decrease in deaths (OS) (PE)
- demonstrated 23 % decrease in progression or deaths (PFS) (PE)
- suggested 24 % decrease in deaths (OS) (extension)
- suggested 23 % decrease in PFS (extension)
|
| |
| CA184-156, 2016 NCT01450761 | RCT | Extensive stage SCLC (Es-SCLC) - 1st Line (L1) | Ipilimumab plus etoposide plus platine | Placebo plus etoposide plus platine | phased induction schedule followed by maintenance in patients with Extensive-Stage Small-Cell Lung Cancer (no prior systemic therapy for ED-SCLC) | 566 / 566 | high
| inconclusive | - inconclusive 6 % decrease in deaths (OS) (PE)
- suggested 15 % decrease in progression or deaths (PFS)
|
| |
| KEYNOTE-604, 2020 NCT03066778 | RCT | Extensive stage SCLC (Es-SCLC) - 1st Line (L1) | pembrolizumab plus etoposide plus platine | placebo plus etoposide plus platine | patients with newly diagnosed Extensive Stage Small Cell Lung Cancer | 228 / 225 | low
| conclusif | - suggested 20 % decrease in deaths (OS) (PE)
- demonstrated 25 % decrease in progression or deaths (PFS) (PE)
|